PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.

ABSTRACT:

Background

Eribulin is a microtubule-targeting agent approved for the treatment of advanced or metastatic breast cancer (BC) previously treated with anthracycline- and taxane-based regimens. PIK3CA mutation is associated with worse response to chemotherapy in oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic BC. We aimed to evaluate the role of phosphoinositide 3-kinase (PI3K)/AKT pathway mutations in eribulin resistance.

Methods

Resistance to eribulin was evaluated in HER2- BC cell lines and patient-derived tumour xenografts, and correlated with a mutation in the PI3K/AKT pathway.

Results

Eleven out of 23 HER2- BC xenografts treated with eribulin exhibited disease progression. No correlation with ER status was dete

SUBMITTER: Gris-Oliver A 

PROVIDER: S-EPMC8076303 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature